Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04066244 · ClinicalTrials.gov registry record · Phase 2
Study of Safety and Proof of the Mechanism of BLZ945 in ALS Patients
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT04066244 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 28 participants.
The verdict
NCT04066244, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
It was an open label study to evaluate safety, tolerability and brain microglia response in participants with Amyotrophic Lateral Sclerosis (ALS) following multiple doses of BLZ945.
Interventions
- DRUG BLZ945
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2019-12-30 |
| Est. Completion | 2024-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04066244
The ClinicalTrials.gov registry entry for NCT04066244 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BLZ945 is the first listed.
NCT04066244 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04066244 about?
NCT04066244 is a clinical study titled "Study of Safety and Proof of the Mechanism of BLZ945 in ALS Patients". It was an open label study to evaluate safety, tolerability and brain microglia response in participants with Amyotrophic Lateral Sclerosis (ALS) following multiple doses of BLZ945.
What is the current status of trial NCT04066244?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2019-12-30. Estimated completion is 2024-02-01.
What interventions are being tested in trial NCT04066244?
The interventions under investigation include: BLZ945 (DRUG).
Who is sponsoring clinical trial NCT04066244?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.